Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Daniel Ter-Minassian"'
Autor:
Chantal Din-Bell, Jana Held, Ali Sié, Carmen L. Ospina Salazar, Sodiomon B. Sirima, Alain Nahum, Léa Nadège Bonkian, Nekoye Otsyula, Lucas Otieno, Ahmed M Abdallah, Peter G. Kremsner, Bertrand Lell, Bancole Moulero, Robert Kimutai, Kimiko Koiwai, Mohamadou Siribié, Elhadj Djeriou, Cathy Cantalloube, Benjamin Mordmüller, Maryvonne Kombila, Marielle K. Bouyou-Akotet, Christian Supan, Daniel Ter-Minassian, Halidou Tinto, John N. Waitumbi, Boubacar Coulibaly
Publikováno v:
The Lancet Infectious Diseases. 15:1409-1419
Summary Background Artemisinin-based combination therapies (ACTs) are the recommended first-line treatment for uncomplicated Plasmodium falciparum malaria. Ferroquine is a new combination partner for fast-acting ACTs such as artesunate. We aimed to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7f0670e21fe687311ae1c2979ef20bc
https://doi.org/10.1016/s1473-3099(15)00079-1
https://doi.org/10.1016/s1473-3099(15)00079-1
Autor:
Paul M. Griffin, James S. McCarthy, Elhadj Djeriou, Rob Hooft van Huijsduijnen, Cathy Cantalloube, Mark Baker, Thomas Rückle, Daniel Ter-Minassian, Jörg J. Möhrle, Peter O'Rourke, Louise Marquart
Publikováno v:
Malaria Journal
Background Ferroquine (SSR97193) is a candidate anti-malarial currently undergoing clinical trials for malaria. To better understand its pharmacokinetic (PK) and pharmacodynamic (PD) parameters the compound was tested in the experimentally induced bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0375bfab59b77b1806ab32c34d1f9b9
https://doi.org/10.1186/s12936-016-1511-3
https://doi.org/10.1186/s12936-016-1511-3
Autor:
Peter G. Kremsner, Michael Ramharter, Saadou Issifou, Christophe Biot, Aziz Filali-Ansary, Ghyslain Mombo-Ngoma, Carmen L. Ospina Salazar, Matthias P. Dal-Bianco, Florent Mazuir, Bertrand Lell, Christian Supan, Daniel Ter-Minassian
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:3165-3173
Ferroquine (SSR97193), a ferrocene-quinoline conjugate, is a promising novel antimalarial currently undergoing clinical evaluation. This study characterizes its pharmacokinetic properties. Young male African volunteers with asymptomatic Plasmodium fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9856a1a794064101803603a4ece9d043
https://doi.org/10.1128/aac.05359-11
https://doi.org/10.1128/aac.05359-11
Autor:
Jamal Khalife, Daniel Ter-Minassian, Laurent Fraisse, Daniel Dive, Christophe Biot, François Nosten
Publikováno v:
Parasite, Vol 18, Iss 3, Pp 207-214 (2011)
Scopus-Elsevier
Parasite : journal de la Société Française de Parasitologie
Parasite
Scopus-Elsevier
Parasite : journal de la Société Française de Parasitologie
Parasite
Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d61a63c4726d6695378cbac0f8180d0
https://doi.org/10.1051/parasite/2011183207
https://doi.org/10.1051/parasite/2011183207
Autor:
Muriel Vray, François Simon, François Bompart, Umberto d’Alessandro, Chantal Belorgey, Pascal Bilbault, Yves Champey, Philippe Deloron, Jean Paul Demarez, Alain Dessein, Christian Funck-Bruntano, Marta Gersberg, François Hirsch, Victor Kandé, Solomon Kapere, Catherine Lassale, Jean Lemerle, Fabrice Pilorgé, Gilles Riveau, Thierry de Rochegonde, Daniel Ter-Minassian
Publikováno v:
Therapies. 62:223-227
On the basis of a review of current clinical research conditions in developing countries, guidelines have been formulated to ensure scientific validity as well as adherence to universal ethical principles. The main recommendation is that projects sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f5e5b9c2ce91926335caea468e894f0
https://doi.org/10.2515/therapie:2007045
https://doi.org/10.2515/therapie:2007045
Autor:
Muriel Vray, François Simon, François Bompart, Umberto d’Alessandro, Chantal Belorgey, Pascal Bilbault, Yves Champey, Philippe Deloron, Jean Paul Demarez, Alain Dessein, Christian Funck-Bruntano, Marta Gersberg, François Hirsch, Victor Kandé, Solomon Kapere, Catherine Lassale, Jean Lemerle, Fabrice Pilorgé, Gilles Riveau, Thierry de Rochegonde, Daniel Ter-Minassian
Publikováno v:
Therapies. 62:217-222
Les conditions dans lesquelles les recherches cliniques sont actuellement menees dans les pays en developpement ont ete revues, et des recommandations pour garantir leur validite scientifique et le respect des regles d'ethique universelles ont ete fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67dfab0aa6d6671c9ea19299579315d8
https://doi.org/10.2515/therapie:2007044
https://doi.org/10.2515/therapie:2007044
Autor:
Michael Ramharter, Pierre-Blaise Matsiegui, Bertrand Lell, Peter G. Kremsner, Matthias P. Dal-Bianco, Ghyslain Mombo-Ngoma, Christian Supan, Carmen L. Ospina Salazar, Michel A. Missinou, Daniel Ter-Minassian, Maryvonne Kombila, Saadou Issifou
Publikováno v:
Malaria Journal, Vol 10, Iss 1, p 53 (2011)
Malaria Journal
Malaria Journal
Background The development and spread of drug resistant Plasmodium falciparum strains is a major concern and novel anti-malarial drugs are, therefore, needed. Ferroquine is a ferrocenic derivative of chloroquine with proven anti-malarial activity aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e4a43f21cd9fbe298d58fe19f9b3c6
https://doi.org/10.1186/1475-2875-10-53
https://doi.org/10.1186/1475-2875-10-53